


CLAIMS:

1. A compound of Formula (I):



Formula (I)

5

wherein:

A is phenyl or a 5- or 6-membered heteroaryl ring, where A is unsubstituted or substituted by one or 2 groups independently selected from R^3 ;

R^1 is selected from hydrogen and methyl;

- 10 R^2 is selected from hydrogen and methyl;

R^3 is selected from methyl, methoxy, fluoro, chloro and cyano;


with the proviso that at least one of R^1 and R^2 is methyl;

or a salt, pro-drug or solvate thereof.

- 15 2. A compound of Formula (I) or a salt, pro-drug or solvate thereof, as claimed in Claim 1, wherein R^1 is methyl.


3. A compound of Formula (I), as claimed in Claim 1 or Claim 2, which is a compound of Formula (Ia), or a salt, pro-drug or solvate thereof; wherein A and R^2 are as defined in

20 Claim 1.




Formula (Ia)

4. A compound of Formula (Ia), as claimed in Claim 3, which is a compound of Formula (Ib), or a salt, pro-drug or solvate thereof.
- 25



Formula (Ib)

5. A compound of Formula (Ia), as claimed in Claim 3, which is a compound of Formula (Ic), or a salt, pro-drug or solvate thereof;



Formula (Ic)


wherein:

A' is heteroaryl.

10

6. A compound of Formula (I), (Ia), (Ib) or (Ic) as claimed in any one of Claims 1 to 5, wherein R² is hydrogen, or a salt, pro-drug or solvate thereof.

7. A compound of Formula (I) as claimed in Claim 1, which is a compound of Formula (Ie); or a salt, pro-drug or solvate thereof,



Formula (Ie)

wherein:

A is selected from phenyl, thienyl and furanyl;

20 A is optionally substituted with methyl, methoxy, chloro or fluoro;

R¹ is selected from hydrogen and methyl;

R^2 is selected from hydrogen and methyl;
with the proviso that at least one of R^1 and R^2 is methyl.

8. A compound of formula (I) as claimed in Claim 1, selected from:
- 5 6-{3-[(1S)-1-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-furan-2-ylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-(2-methoxyphenyl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-
- 10 benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-thien-2-ylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-(5-chlorothien-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 15 6-{3-[(1S)-1-methyl-2-thien-3-ylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-(5-methylfuran-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-{4-fluorophenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-
- 20 benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(2S)-2-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(2R)-2-methyl-2-phenylethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid; and
- 25 6-{3-[(1S)-1-methyl-2-{2-chlorophenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-{3,5-difluorophenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-{3-fluorophenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-
- 30 benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-(5-methylthiophen-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;
- 6-{3-[(1S)-1-methyl-2-{3-methoxyphenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-

benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-{2-methylphenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-{4-methoxyphenyl}ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-

5 benzoylamino}-3-pyridine carboxylic acid;

6-{3-[(1S)-1-methyl-2-(5-chlorofuran-2-yl)ethoxy]-5-[(1S)-2-methoxy-1-methylethoxy]-benzoylamino}-3-pyridine carboxylic acid;

or a salt, pro-drug or solvate thereof.

10 9. A pharmaceutical composition comprising a compound of Formula (I) as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, together with a pharmaceutically-acceptable diluent or carrier.

10. A compound of Formula (I), as claimed in any one of Claims 1 to 8, or a salt, solvate
15 or prodrug thereof, for use as a medicament.

11. A compound of Formula (I), as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, for use in the preparation of a medicament for treatment of a disease mediated through GLK, in particular type 2 diabetes.

20

12. A method of treating GLK mediated diseases, especially diabetes, by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or a salt, solvate or prodrug thereof, to a mammal in need of such treatment.

25 13. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the combined treatment or prevention of diabetes and obesity.


14. The use of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, in the preparation of a medicament for use in the treatment or
30 prevention of obesity.

15. A method for the combined treatment of obesity and diabetes by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

5 16. A method for the treatment of obesity by administering an effective amount of a compound of Formula (I), as claimed in any one of Claims 1 to 8, or salt, solvate or pro-drug thereof, to a mammal in need of such treatment.

17. A process for the preparation of a compound of Formula (I) as claimed in Claim 1, a
10 salt, pro-drug or solvate thereof which comprises:

(a) reaction of an acid of Formula (IIIa) or activated derivative thereof with a compound of Formula (IIIb),




Formula (IIIa)

Formula (IIIb),

15 wherein P¹ is H or a protecting group; or


(b) de-protection of a compound of Formula (IIIc),




Formula (IIIc)

wherein P¹ is a protecting group; or

20 (c) reaction of a compound of Formula (IIId) with a compound of Formula (IIIe),




Formula (IIIId)




Formula (IIIe)

wherein X^1 is a leaving group and X^2 is a hydroxyl group or X^1 is a hydroxyl group and X^2 is a leaving group, and wherein P^1 is a protecting group; or

- 5 (d) reaction of a compound of Formula (IIIff) with a compound of Formula (IIIg)




Formula (IIIff)




Formula (IIIg)

wherein X^3 is a leaving group and X^4 is a hydroxyl group or X^3 is a hydroxyl group and X^4 is a leaving group; or

- 10 (e) reaction of a compound of Formula (IIIh) with a compound of Formula (IIIi),



Formula (IIIh)



Formula (IIIi);

wherein X^5 is a leaving group and wherein P^1 is H or a protecting group;

and thereafter, if necessary:

- 15 i) converting a compound of Formula (I) into another compound of Formula (I);
- ii) removing any protecting groups;
- iii) forming a salt, pro-drug or solvate thereof.